


ΕΠΙΘΕΤΙΚΑ ΛΕΜΦΩΜΑΤΑ

Πρωτοπαθή Λεμφώματα Μεσοθωρακίου
Πρωτοπαθή Λεμφώματα ΚΝΣ

Στον Πραγματικό Κόσμο ?

Η ΝΕΑ ΕΠΟΧΗ

ΣΤΙΣ ΜΕΛΕΤΕΣ, ΣΤΙΣ "ΜΕΛΕΤΕΣ" ΚΑΙ ΣΤΟ NCI




Στον Πραγματικό Κόσμο

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience

Επιλογή Ασθενών



Ηλικιωμένοι


TO THE EDITOR:

Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study

**4th INTERNATIONAL CONFERENCE ON
HEMATOLOGIC MALIGNANCIES AT OLDER AGE: BIOLOGY AND THERAPY**


Λεμφώματα Μεσοθωρακίου ...στο NCI

R/EPOCH




Στην Ελλάδα !

Rituximab/CHOP (+/- RT)




T. Basilakopoulos


Λεμφώματα ΚΝΣ ...στο Memorial



...και στην Κίνα



Λεμφώματα ΚΝΣ στη Βοστώνη



- ✓ Ηλικία >60
- ✓ PS >1
- LDH >1
- CSF Protein
- ✓ Βαθιές εντοπίσεις

Λεμφώματα ΚΝΣ

Μελέτη ... Ib

Characteristics	Values
Median age (range), y	62 (23-74)
Sex, n (%)	
Male	8 (53)
Female	7 (47)
Median ECOG score (range)	1 (0-2)
CNSL, n (%)	
PCNSL	9 (60)
SCNSL	6 (40)
Disease status, n (%)	
Recurrent PCNSL or SCNSL	9 (60)
Refractory PCNSL or SCNSL	3 (20)
Newly diagnosed SCNSL	3 (20)
Newly diagnosed PCNSL	0 (0)
CNS involvement, n (%)	
Brain	5 (33)
CSF	2 (13)
Brain and CSF	7 (47)
Brain and eye	1 (7)
Prior treatment in r/r disease, n (%); n = 12	
Chemotherapy	12 (100)
HD-MTX chemotherapy	12 (100)
HD-MTX + alkylator	9 (75)
Rituximab	12 (100)
Radiation	1 (8)
Stem cell transplant	1 (8)
HD-MTX at recurrence	3 (25)
Median number of prior regimens (range)	1 (0-2)
Corticosteroids at enrollment, n (%)	5 (33)



Λεμφώματα ΚΝΣ ...και άλλη μελέτη

Patient Characteristics

Characteristics	Number	Percent
Total Enrolled	18	100
Age Median (Range)	66 (49–87) years	
Male sex	11	61
ECOG Performance Status		
1	13	72
2	3	17
3	2	11
Histology: Large B-cell lymphoma (PCNSL)	18	100
Untreated PCNSL	5	28
Previously treated PCNSL	13	72
Median (range) regimens	2 (1–6)	
Treatment refractory	11	85
Prior methotrexate	13	100
Prior rituximab	12	92
Prior cranial radiation	4	31
Autologous Transplant	4	31
Disease sites		
CSF + Flow cytometry	9	50
Intraocular	3	11
Deep brain lesions	13	72
Peripheral Disease	3	11
Elevated LDH	10	56
IELSG risk groups		
0–1	3	17
2–3	7	39
4–5	8	44